Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results beating Wall Street’s revenue expectations , with sales up 10.9% year on year to $9.09 billion. The company’s full-year revenue ...

In 2024, when Amgen generated $33.4 billion in revenue, more than $2.2 billion came from sales of its biosimilars. It was a 16% increase from Amgen’s biosimilar sales in 2023 and the company ...

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth. Amgen specializes in biotechnology as it seeks to advance medical therapeutics.

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

A 12-month price target for AMGN of $365/share is put forward based on a 5.6x multiple of the midpoint of 2025 sales guidance, reflecting confidence in Amgen's growth trajectory. I have previously ...

Biopharmaceutical company Amgen (AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after ...

Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results beating Wall Street’s revenue expectations , with sales up 10.9% year on year to $9.09 billion. The company’s full-year revenue guidance ...